GlassScriptPhysician profile
Richard M Silver
NPI 1275641219
$82,248.58
in general payments reported to CMS, 2019-2025
18 companies · $2,986 in 2025
The $2,986 reported for 2025 was more than what 77% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $28K · 2021: $16K · 2022: $1,498 · 2023: $14.04 · 2024: $6,918 · 2025: $2,986.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,995 · Travel and Lodging: $1,575 · Food and Beverage: $291 · Education: $56.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,995.00 |
| Travel and Lodging | $1,574.65 |
| Food and Beverage | $290.84 |
| Education | $56.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $62,145.51 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $6,717.72 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $6,561.69 | 2019 | |
| Boehringer Ingelheim International Gmbh | $3,961.66 | 2019-2020 | |
| Csl Behring | $2,020.08 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $400.00 | 2024-2025 | |
| Abbvie INC. | $160.51 | 2023-2025 | Rinvoq |
| Glaxosmithkline, LLC. | $126.45 | 2019 | |
| Janssen Biotech, INC. | $75.11 | 2025 | Tremfya |
| Genentech, INC. | $49.95 | 2021 | |
| Allergan, INC. | $15.06 | 2019 | |
| Ucb, INC. | $14.84 | 2025 | Bimzelx |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Silver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.